For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Taiho Licenses Antiemetic Combination Drug from Helsinn
April 25, 2011
- Takeda, Samyang to Collaborate for RNAi DDS Tech
April 25, 2011
- New ARB EDARBI Launched in the US: Takeda
April 25, 2011
- Takeda Starts PIII Trial of AMG479 in Metastatic Pancreatic Cancer
April 25, 2011
- Tsumura Establishes Licorice Cultivation Methods in China
April 25, 2011
- OPF to Codevelop DIABECELL with LCT for Islet Replacement Therapy
April 25, 2011
- Mochida to Resume Full Production of Oral Drugs by Late June
April 25, 2011
- CytRx to Develop TMRC's Tamibarotene for NSCLC in North America
April 25, 2011
- Mohrus Tape Production Partially Recovers at Hisamitsu Factory
April 25, 2011
- Shipment of Hundreds of Drug Brands Affected by Quake
April 25, 2011
- NEW PRODUCTS
April 25, 2011
- Bayer Yakuhin Aims at Sales of Over ¥200 Bil. in 2-3 Years
April 25, 2011
- Xience V More Significantly Reduces MACE than Taxus: Abbott
April 25, 2011
- Novartis Discontinues PIII Study of Tasigna in GIST
April 25, 2011
- Wholesalers Less Pessimistic than Manufacturers about Quake's Effects on Demand
April 25, 2011
- Korosho Wants Industry “As a Whole”to Meet Power Cut Targets
April 25, 2011
- 4 Unapproved Indications Considered to Have Unmet Medical Needs: Council
April 25, 2011
- The Great East Japan Earthquake: MRs in the Disaster Zone
April 25, 2011
- No Company Subject to Penalty due to Failure to Develop Designated Unapproved Drugs/Indications
April 25, 2011
- Lantus Obtains 60% Market Share: sanofi-aventis
April 25, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…